Stockscreener 앱 받기
27.74
3.61%
-1.04
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
Understanding Momentum Shifts in (ARQT) - Stock Traders Daily
Could Arcutis (ARQT) Infant Label Bid Clarify the Limits of Its Single-Drug Strategy? - simplywall.st
BREAKING: US FDA Sets PDUFA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology Digest
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis gets FDA review for Zoryve 0.05% label expansion (ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Receives FDA Acceptance for Zoryve Cream - GuruFocus
FDA accepts Arcutis application for infant eczema treatment - Investing.com
Arcutis: FDA to Review Zoryve for Atopic Dermatitis in Infants - Moomoo
FDA accepts Arcutis application for infant eczema treatment By Investing.com - Investing.com India
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - The Manila Times
FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (Roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Arcutis Biotherapeutics (ARQT) Rises 4.6% as Biotech Sector Momentum Drives Shares HigherResistance Breakout Stocks - dars.gov.et
Price to sales forward of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
3 Healthcare Stocks Built For Higher Rates And Steady Demand - Sahm
Arcutis Biotherapeutics (ARQT) Edges Lower, Tests Key Support Levels Amid ConsolidationEquity Put Call - dars.gov.et
Comparative Analysis of Arcutis and Vertex Biotherapeutics - Intellectia AI
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? - The Motley Fool
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis lures 9 new hires with 61,000 stock awards - Stock Titan
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis launches virtual dermatology platform for skin conditions By Investing.com - Investing.com India
Arcutis Launches Virtual Dermatology Platform to Boost Access to Roflumilast - The Dermatology Digest
Avoiding Lag: Real-Time Signals in (ARQT) Movement - Stock Traders Daily
Arcutis launches virtual dermatology platform for skin conditions - Investing.com
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications - The Manila Times
Arcutis’ new virtual dermatology platform targets care gaps for 45M Americans - Stock Titan
FDA approves Zoryve cream for plaque psoriasis in children age 2+ - Investing.com India
FDA approves Zoryve cream for plaque psoriasis in children age 2+ By Investing.com - Investing.com India
Arcutis Biotherapeutics stock edges lower with bullish trend intact after once-daily cream approval - Traders Union
Arcutis Biotherapeutics (ARQT) Secures FDA Approval for ZORYVE C - GuruFocus
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2 - The Manila Times
Arcutis Biotherapeutics Announces FDA Approval of Expanded ZORYVE Cream 0.3% Indication for Children With Plaque Psoriasis Down to Age 2 - Quiver Quantitative
FDA broadens Arcutis’ ZORYVE to children as young as 2 - Stock Titan
Arcutis Biotherapeutics (ARQT) Edges Higher as Bullish Momentum BuildsBreakout Trade - dars.gov.et
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $36 - Moomoo
Arcutis Biotherapeutics Inc Actuals & Estimates (NASDAQ:ARQT) - TradingView
ARQT Forecast — Price Target — Prediction for 2027 - TradingView
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Globe and Mail
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% - The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price - ChartMill
Discipline and Rules-Based Execution in ARQT Response - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Holds Steady Near Support as Investors Eye ResistanceBearish Pattern Stocks - dars.gov.et
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Arcutis director Sue-Jean Lin sells $120,586 in company shares By Investing.com - Investing.com Australia
Insider Sell Alert: Sue-jean Lin Sells Shares of Arcutis Biother - GuruFocus
Arcutis director Sue-Jean Lin sells $120,586 in company shares - Investing.com
Arcutis Biotherapeutics Inc (ARQT) Institutional Confidence - TradingKey
Arcutis (ARQT) director Sue-Jean Lin executes planned share sale - Stock Titan
Arcutis (ARQT) director trades shares under Rule 10b5-1 stock plan - Stock Titan
Arcutis Biotherapeutics Inc (ARQT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arcutis Biotherapeutics Inc (ARQT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
2.64%
자본화:
|
볼륨(24시간):